

Axel Hinke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5285480/publications.pdf>

Version: 2024-02-01

10
papers

329
citations

1163117

8
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

539
citing authors

#	ARTICLE	IF	CITATIONS
1	Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies. <i>Cancer Treatment Reviews</i> , 2021, 97, 102202.	7.7	14
2	Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102226.	7.7	8
3	Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial. <i>Clinical Chemistry</i> , 2020, 66, 1510-1520.	3.2	11
4	Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. <i>European Journal of Cancer</i> , 2018, 101, 105-113.	2.8	19
5	Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study. <i>BMC Cancer</i> , 2018, 18, 51.	2.6	17
6	Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial. <i>Clinical Colorectal Cancer</i> , 2018, 17, e733-e739.	2.3	7
7	Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany. <i>Oncologist</i> , 2017, 22, 131-138.	3.7	9
8	Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials. <i>British Journal of Cancer</i> , 2017, 117, 1768-1776.	6.4	10
9	Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2015, 16, 1355-1369.	10.7	228
10	Trastuzumab Single-Drug Therapy after Failure of Cytotoxic Treatment for Metastatic Breast Cancer. <i>Onkologie</i> , 2010, 33, 425-430.	0.8	6